Bank of America
NBIX icon

Bank of America’s Neurocrine Biosciences NBIX Stock Holding History

Bank of America’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-106,000
Closed -$14.9M – 8034
2025
Q3 		$14.9M Buy
+106,000
New +$14.4M ﹤0.01% 2892
2023
Q4 		– Sell
-10,000
Closed -$1.13M – 8154
2023
Q3 		$1.13M Buy
+10,000
New +$1.05M ﹤0.01% 4735
2020
Q3 		– Sell
-24,200
Closed -$2.95M – 7078
2020
Q2 		$2.95M Buy
24,200
+7,600
+46% +$840K ﹤0.01% 3312
2020
Q1 		$1.44M Buy
16,600
+13,500
+435% +$1.32M ﹤0.01% 3746
2019
Q4 		$333K Sell
3,100
-41,900
-93% -$4.39M ﹤0.01% 5302
2019
Q3 		$4.05M Sell
45,000
-21,200
-32% -$1.98M ﹤0.01% 3401
2019
Q2 		$5.59M Buy
66,200
+10,600
+19% +$870K ﹤0.01% 3123
2019
Q1 		$4.9M Buy
55,600
+10,500
+23% +$878K ﹤0.01% 3187
2018
Q4 		$3.22M Sell
45,100
-33,700
-43% -$3.23M ﹤0.01% 3435
2018
Q3 		$9.69M Sell
78,800
-91,500
-54% -$10.4M ﹤0.01% 2503
2018
Q2 		$16.7M Sell
170,300
-20,500
-11% -$1.84M ﹤0.01% 1971
2018
Q1 		$15.8M Buy
190,800
+109,800
+136% +$9.27M ﹤0.01% 1993
2017
Q4 		$6.29M Buy
+81,000
New +$5.52M ﹤0.01% 2916
2017
Q3 		– Sell
-13,500
Closed -$621K – 7189
2017
Q2 		$621K Hold
13,500
– – ﹤0.01% 4766
2017
Q1 		$585K Buy
+13,500
New +$578K ﹤0.01% 4787
2016
Q2 		– Sell
-50,000
Closed -$1.98M – 7278
2016
Q1 		$1.98M Buy
+50,000
New +$1.98M ﹤0.01% 3578
2015
Q2 		– Sell
-60,000
Closed -$2.38M – 7364
2015
Q1 		$2.38M Sell
60,000
-53,600
-47% -$1.92M ﹤0.01% 3077
2014
Q4 		$2.54M Buy
113,600
+109,200
+2,482% +$2.07M ﹤0.01% 3140
2014
Q3 		$69K Buy
4,400
+4,300
+4,300% +$64.3K ﹤0.01% 6297
2014
Q2 		$1K Sell
100
-2,500
-96% -$35.3K ﹤0.01% 7910
2014
Q1 		$42K Buy
+2,600
New +$44.5K ﹤0.01% 6526
2013
Q3 		– Sell
-38,400
Closed -$514K – 7979
2013
Q2 		$514K Buy
+38,400
New +$472K ﹤0.01% 4719

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bank of America's NBIX Position: Q2 2026 in Review

Bank of America increased its Neurocrine Biosciences (NBIX) stake by 6.1% in Q2 2026, buying an estimated $5.27M and bringing the position to 619,352 shares worth $104M. The position accounts for 0.01% of the portfolio, ranked #1158.

Bank of America first reported a position in NBIX in Q2 2013 and has held it in 53 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Bank of America held 619,352 shares of Neurocrine Biosciences worth $104M as of Q2 2026.
  • Bank of America bought 35,525 Neurocrine Biosciences shares in Q2 2026, an estimated $5.27M.
  • Neurocrine Biosciences made up 0.01% of Bank of America's portfolio in Q2 2026, its #1158 holding.
  • Bank of America first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 53 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.